newsfilter
← Latest News
GlobeNewswire·

NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors

Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and expected to enroll up to approximately 80 patients